Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

American Family Physician December 1, 2003 Gill et al.	Diagnosis of Systemic Lupus Erythematosus Systemic lupus erythematosus is a multisystem inflammatory disease that is often difficult to diagnose. Before the diagnosis can be established, four of 11 clinical and laboratory criteria must be met.
American Family Physician September 15, 2003 Richie & Francis	Diagnostic Approach to Polyarticular Joint Pain Polyarticular joint pain (i.e., pain in more than four joints) poses a diagnostic challenge because of the extensive differential diagnosis. Consequently, family physicians need to keep the diagnosis open in evaluating patients who present with pain in multiple joints.
American Family Physician July 15, 2006 Junnila & Cartwright	Chronic Musculoskeletal Pain in Children: Part II. Rheumatic Causes Primary care physicians should have a working knowledge of rheumatic diseases of childhood that manifest primarily as musculoskeletal pain. Children with juvenile rheumatoid arthritis can present with painless joint inflammation and may have normal results on rheumatologic tests.
American Family Physician July 1, 2006 Junnila & Cartwright	Chronic Musculoskeletal Pain in Children: Part I. Initial Evaluation Musculoskeletal pain can be difficult for children to characterize. A logical and consistent approach to diagnosis is recommended, with judicious use of laboratory and radiologic testing.
American Family Physician November 1, 2001 Ric Anthony Koler	Dermatomyositis Dermatomyositis is an idiopathic inflammatory myopathy with characteristic skin manifestations. Although the disorder is rare, early recognition and treatment are important ways to decrease the morbidity of systemic complications...
American Family Physician September 15, 2005 Rindfleisch & Muller	Diagnosis and Management of Rheumatoid Arthritis Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.8 percent of the adult population worldwide. It is a lifelong disease, although patients can go into remission. Physicians must be aware of common comorbidities.
Nursing August 2009 Pullen et al.	Putting a face on systemic lupus erythematosus In this article, we'll tell you how to assess a patient for SLE and what to teach her about managing this chronic disorder.
American Family Physician September 15, 2002 Patel & Lundy	Ocular Manifestations of Autoimmune Disease Because a number of these diseases may initially present with ocular symptoms, physicians should maintain a high index of suspicion to make a timely diagnosis. A thorough ophthalmic examination should be completed.
American Family Physician April 1, 2005 Aaron Saguil	Evaluation of the Patient with Muscle Weakness Muscle weakness is a common complaint among patients presenting to family physicians. Diagnosis begins with a patient history distinguishing weakness from fatigue or asthenia, separate conditions with different etiologies that can coexist with, or be confused for, weakness.
Chemistry World March 15, 2011 Sarah Houlton	Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration
American Family Physician December 1, 2003 Roth & Basello	Approach to the Adult Patient with Fever of Unknown Origin A thorough history, physical examination, and standard laboratory testing remain the basis of the initial evaluation of the patient with FUO.
American Family Physician March 15, 2004	Nail Abnormalities: Clues to Systemic Disease The visual appearance of the fingernails and toenails may suggest an underlying systemic disease.
American Family Physician April 15, 2002 Rajani Katta	Cutaneous Sarcoidosis: A Dermatologic Masquerader Sarcoidosis is a multisystem disease that may involve almost any organ system; therefore, it results in various clinical manifestations. Cutaneous sarcoidosis occurs in up to one third of patients with systemic sarcoidosis. Recognition of cutaneous lesions is important...
Nursing July 2011 Susan Simmons	Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.
American Family Physician July 1, 2003 Siva et al.	Diagnosing Acute Monoarthritis in Adults: A Practical Approach Acute monoarthritis can be the initial manifestation of many joint disorders. Because patients with acute monoarthritis often present to their family physician, a proper diagnostic approach is important.
American Family Physician June 15, 2004 Kataria, & Brent	Spondyloarthropathies Identification, features and strength of recommendations of this diverse group of inflammatory arthritides.
Chemistry World November 4, 2009 Phil Taylor	New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.
The Motley Fool March 9, 2010 Brian Orelli	The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
American Family Physician September 15, 2001 David S. Smith	Health Care Management of Adults with Down Syndrome The family physician's holistic approach to patients forms the basis of good health care for adults with Down syndrome...
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
Chemistry World September 25, 2013 Phillip Broadwith	Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Chemistry World June 19, 2012 Anthony King	Nanoparticles linked to rheumatoid arthritis Three types of nanoparticles were found to ramp up protein citrullination in cell cultures, a change that can make the body think native proteins are foreign. This process has previously been linked to autoimmune disease.
Chemistry World September 3, 2014 Phillip Broadwith	Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool October 26, 2011 Brian Orelli	Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest.
Chemistry World February 4, 2014 Phillip Broadwith	Merck & Co doubles up on Ablynx research deal This collaboration will focus on nanobodies (antibody fragments) directed against cancer.
The Motley Fool July 20, 2009 Brian Orelli	Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.
The Motley Fool December 30, 2011 Brian Orelli	A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace.
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
The Motley Fool October 5, 2005 Stephen D. Simpson	Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Lupus: How Big will Benlysta Become? Human Genome Sciences/GSK's Benlysta (belimumab) was approved by an FDA advisory committee in November -- to the cheers of many patients who had testified to their need of the novel therapy.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.